In a phase 1b/2a trial of 58 adults with HFrEF, oral AC01 (ghrelin receptor agonist inotrope) for up to 28 days appeared safe: no AC01-related serious adverse events or deaths; mild/moderate adverse events in 80% on AC01 vs 71% on placebo.
RCTn = 58
Lund et al. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study